AbbVie notified staff that it will end its 11-year collaboration with Alphabet’s Calico Labs and is preparing layoffs tied to the wind‑down of joint aging projects. The partnership — which AbbVie and Calico renewed multiple times and backed with more than $1.5 billion in R&D funding — is being closed as AbbVie shifts away from small‑molecule discovery toward injectables and genetic medicines. Assets developed under the collaboration, including the eIF2B-targeted fosigotifator program that failed in neurodegeneration trials, face uncertain futures.